News
Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...
Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.
"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...
Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...
The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine, but with unusual ...
Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization ...
Explore more
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.
Trump admin's new FDA update limits annual COVID shots to high-risk groups, ending routine access for healthy kids and adults ...
In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...
The FDA is tightening its regulatory policy around COVID vaccines with a new framework that raises the bar for certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results